SBS, or short bowel syndrome, is a condition where the small intestine doesn’t work properly, leading to malabsorption. Diarrhea is one of the primary symptoms of SBS, which can cause malnutrition, dehydration, and significant weight loss in many patients. Failure to address this condition can result in complications like kidney stones and anemia. In children, intestinal blockages, or obstructions, damaged intestinal tissue, gastroschisis, and malrotation (also known as rotation of the midgut) are the main causes of SBS, whereas in adults, it can be caused by mesenteric ischemia, radiation enteritis, and Crohn’s disease. Typically, SBS arises due to the surgical removal of a significant portion of the small intestine.
Request a sample report for a detailed analysis of key players and full segmentation: @ https://www.coherentmarketinsights.com/insight/request-sample/169
Short bowel syndrome imposes a substantial healthcare burden, particularly in nations with low incomes.
The Crohn’s & Colitis Foundation of America reported that in 2010, there were 10,000–20,000 documented cases of short bowel syndrome, and 25% of those individuals experienced complications within two years of diagnosis. Due to a decrease in absorption rates and inadequate nutrient intake, many children with short bowel syndrome die from malnutrition. Sancilio and Company, Inc. states that most cases of short bowel syndrome are caused by congenital anomalies, such as midgut rotation, which typically results in death before the age of six. Nutrinia Ltd. states that current treatment methods for infants with short bowel syndrome involve a combination of nutritional, pharmacological, and surgical interventions aimed at promoting enteral nutrition while minimizing the challenges of parenteral nutrition therapy. Long-term parenteral treatment is administered to a majority of patients, causing adverse effects and significantly elevating the risk of liver disease, infections, and other complications. Infants suffering from severe short bowel syndrome experience challenges related to intestinal failure-related liver disease, bloodstream infections, and bacterial overgrowth. In addition, the use of parenteral nutrition imposes a significant economic burden on society and the healthcare system, with estimated annual costs ranging from US$ 180,000 to US$ 570,000 and beyond.
The GLP-2 drug category is the prevailing leader in the North American and European markets.
The global short bowel syndrome market is categorized by geography and drug class. The drug class segment includes GLP-2, glutamine, growth hormone, and other drugs.
The rising use of Gattex Therapy to treat short bowel syndrome in North America presents a promising opportunity for expansion.
Coherent Market Insights has segmented the short bowel syndrome market by region into Latin America, Africa, the Middle East, North America, Asia Pacific, and Europe. North America has the largest market share globally, primarily due to the presence of prominent players and the early adoption of advanced medical technologies in countries such as Canada and the United States. In 2008, the National Institute of Diabetes and Digestive and Kidney Disease reported that over 2,000 intestinal transplants were performed in the United States, with 75% of the population being between 18 and 20 years of age. This figure is projected to increase annually, consequently driving growth in the short bowel syndrome market.
Top companies in the global short bowel syndrome market
Top companies including Shire plc, Merck KGaA, Sancilio & Company Inc., GLyPharma Therapeutic, Inc., Zealand Pharma A/S, Nutrinia Ltd., Ardelyx, Inc., OxThera, Emmaus Life Sciences, Inc., and Naia Pharmaceuticals, Inc. are operating the short bowel syndrome market. Leading firms within the short bowel syndrome industry are persistently striving to introduce cutting-edge products and reduce manufacturing expenses to improve their bottom line. As an illustration, Nutrinia Ltd., which intends to initiate a crucial clinical trial of a drug designed to alleviate short bowel syndrome and which has the potential to benefit countless patients around the world by diminishing their reliance on parenteral nutrition and the consequent risk of liver infection.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/169
Reasons to Purchase This Report
• Current and future of Short Bowel Syndrome Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
The Short Bowel Syndrome Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Short Bowel Syndrome Research Findings and Conclusion, Appendix, methodology and data source
Direct Purchase This Report with Huge Discount ( Up To 25% Off) @ https://www.coherentmarketinsights.com/insight/buy-now/169
About Us
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837